## Effect of Emotional Intelligence Training on Methadone-Treated Methamphetamine Users in Qazvin, Iran

Seyed Mohsen Zamir<sup>1</sup>, <u>Mahshid Khazaei</u>, Seyed Hossein Ghafeleh-Bashi<sup>1</sup>, Samira Dodangeh<sup>2</sup>

## **Original Article**

## **Abstract**

DOI: 10.22122/ahj.v14i1.1231

**Background:** Drug users have lower emotional intelligence (EQ) than other members of society. This study aimed to determine the effect of EQ training on methadone-treated methamphetamine (meth) users.

Methods: This randomized clinical trial with a pretest-posttest control group design was conducted on methadone-treated meth users referring to the Drop-in Center in Qazvin, Iran. The subjects completed the Wechsler Adult Intelligence Scale (WAIS), and those who scored higher than 80 (n=70) were entered into the study and randomly divided into the intervention and control groups. The Bar-On Emotional Quotient Inventory (Bar-On EQ-i) was administered for both groups. Subsequently, the intervention group participated in weekly 90-minute EQ training sessions for 4 sessions held by a psychiatric assistant. However, the control group received no intervention. Both groups were re-evaluated by the Bar-On EQ-i 3 months after the end of the training sessions. Eventually, qualitative and quantitative variables were compared between the two groups using an independent t-test and chi-square test, respectively.

**Findings:** Based on the results, the EQ training program could significantly improve the EQ score in the intervention group (P = 0.03). Nevertheless, it showed no effect on reducing meth use (P = 0.13).

**Conclusion:** EQ training for meth users could increase EQ. Nonetheless, further studies with more effective methods are required to reduce meth use.

Keywords: Emotional intelligence; Methadone; Methamphetamine; Iran

Citation: Zamir SM, Khazaei M, Ghafeleh-Bashi SH, Dodangeh S. Effect of Emotional Intelligence Training on Methadone-Treated Methamphetamine Users in Qazvin, Iran. Addict Health 2022; 14(1): 7-14.

**Received:** 23.08.2021 **Accepted:** 26.10.2021

<sup>1-</sup> Department of Psychiatry, Clinical Research Development Unit, 22 Bahman Hospital, Qazvin University of Medical Sciences, Qazvin, Iran

<sup>2-</sup> Medical Microbiology Research Center, Qazvin University of Medical Sciences, Qazvin, Iran Correspondence to: Mahshid Khazaei; Department of Psychiatry, Clinical Research Development Unit, 22 Bahman Hospital, Qazvin University of Medical Sciences, Qazvin, Iran; Email: mahshidkhazaei64@gmail.com